Evidence map›Paper›PMID 32374822›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Randomized Trial Evaluating Clinical Impact of RAPid IDentification and Susceptibility Testing for Gram-negative Bacteremia: RAPIDS-GN.

Ritu Banerjee, Lauren Komarow, Abinash Virk, Nipunie Rajapakse, Audrey N Schuetz, Brenda Dylla, Michelle Earley, Judith Lok, Peggy Kohner, Sherry Ihde and 12 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03218397 (Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia), which is not on this map. Cited by 89 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 3 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03218397 nacompletednot on this map

Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia (RAPIDS-GN)

TypeinterventionalSponsorDuke UniversityRan2017 to 2018Enrolled500ConditionsGram-negative BacteremiaArmsAccelerate PhenoTest™ BC Kit, Standard Culture and AST
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 3 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Clinical impact and cost-consequence analysis of ePlex® blood culture identification panels for the rapid diagnosis of bloodstream infections: a single-center randomized controlled trial.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Trial
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Rapid AST in practice - a workflow analysis of the QuickMICFrontiers in cellular and infection microbiology · 2026
    Article
  19. Impact of rapid molecular testing on clinical outcomes for methicillin-susceptibleAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026
    Article
  20. Multicenter evaluation of the QuickMICEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Ritu BanerjeeDivision of Pediatric Infectious Diseases, Vanderbilt University, Nashville, Tennessee, USA.
Lauren KomarowBiostatistics Center, George Washington University, Rockville, Maryland, USA.
Abinash VirkDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Nipunie RajapakseDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Audrey N SchuetzDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Brenda DyllaDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Michelle EarleyBiostatistics Center, George Washington University, Rockville, Maryland, USA.
Judith LokDepartment of Mathematics and Statistics, Boston University, Boston, Massachusetts, USA.
Peggy KohnerDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Sherry IhdeDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Nicolynn ColeDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Lisa HinesDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Katelyn ReedDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Omai B GarnerDivisions of Pathology and Infectious Diseases, University of California, Los Angeles, California, USA.
Sukantha ChandrasekaranDivisions of Pathology and Infectious Diseases, University of California, Los Angeles, California, USA.
Annabelle de St MauriceDivisions of Pathology and Infectious Diseases, University of California, Los Angeles, California, USA.
Meganne KanataniDivisions of Pathology and Infectious Diseases, University of California, Los Angeles, California, USA.
Jennifer CurelloDivisions of Pathology and Infectious Diseases, University of California, Los Angeles, California, USA.
Rubi AriasDivisions of Pathology and Infectious Diseases, University of California, Los Angeles, California, USA.
William SwearingenDivisions of Pathology and Infectious Diseases, University of California, Los Angeles, California, USA.
Sarah B DoernbergDivision of Infectious Diseases, University of California, San Francisco, California, USA.
Robin PatelDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USUniversity of California, Los Angeles · USGeorge Washington University · USBoston University · USUniversity of California, San Francisco · USVanderbilt University · US

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

backgroundRapid blood culture diagnostics are of unclear benefit for patients with gram-negative bacilli (GNB) bloodstream infections (BSIs). We conducted a multicenter, randomized, controlled trial comparing outcomes of patients with GNB BSIs who had blood culture testing with standard-of-care (SOC) culture and antimicrobial susceptibility testing (AST) vs rapid organism identification (ID) and phenotypic AST using the Accelerate Pheno System (RAPID).

methodsPatients with positive blood cultures with Gram stains showing GNB were randomized to SOC testing with antimicrobial stewardship (AS) review or RAPID with AS. The primary outcome was time to first antibiotic modification within 72 hours of randomization.

resultsOf 500 randomized patients, 448 were included (226 SOC, 222 RAPID). Mean (standard deviation) time to results was faster for RAPID than SOC for organism ID (2.7 [1.2] vs 11.7 [10.5] hours; P < .001) and AST (13.5 [56] vs 44.9 [12.1] hours; P < .001). Median (interquartile range [IQR]) time to first antibiotic modification was faster in the RAPID arm vs the SOC arm for overall antibiotics (8.6 [2.6-27.6] vs 14.9 [3.3-41.1] hours; P = .02) and gram-negative antibiotics (17.3 [4.9-72] vs 42.1 [10.1-72] hours; P < .001). Median (IQR) time to antibiotic escalation was faster in the RAPID arm vs the SOC arm for antimicrobial-resistant BSIs (18.4 [5.8-72] vs 61.7 [30.4-72] hours; P = .01). There were no differences between the arms in patient outcomes.

conclusionsRapid organism ID and phenotypic AST led to faster changes in antibiotic therapy for gram-negative BSIs. CLINICAL TRIALS REGISTRATION: NCT03218397.

Indexed as

BacteremiaGram-Negative Bacterial InfectionsAnti-Bacterial AgentsBlood CultureGram-Negative BacteriaHumansMicrobial Sensitivity TestsAnti-Bacterial Agentsantibiotic susceptibility testingblood culturesbloodstream infectiongram negativerapid diagnostic

Identifiers

PMID32374822
PMCPMC8246790
OpenAlexW3022292221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.